CA3001395A1 - High avidity hpv t-cell receptors - Google Patents

High avidity hpv t-cell receptors Download PDF

Info

Publication number
CA3001395A1
CA3001395A1 CA3001395A CA3001395A CA3001395A1 CA 3001395 A1 CA3001395 A1 CA 3001395A1 CA 3001395 A CA3001395 A CA 3001395A CA 3001395 A CA3001395 A CA 3001395A CA 3001395 A1 CA3001395 A1 CA 3001395A1
Authority
CA
Canada
Prior art keywords
tcr
cell
seq
chain
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3001395A
Other languages
English (en)
French (fr)
Inventor
Thomas Blankenstein
Gerald WILLIMSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of CA3001395A1 publication Critical patent/CA3001395A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3001395A 2015-10-16 2016-10-13 High avidity hpv t-cell receptors Pending CA3001395A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15190230.1A EP3156067A1 (en) 2015-10-16 2015-10-16 High avidity hpv t-cell receptors
EP15190230.1 2015-10-16
PCT/EP2016/074612 WO2017064198A1 (en) 2015-10-16 2016-10-13 High avidity hpv t-cell receptors

Publications (1)

Publication Number Publication Date
CA3001395A1 true CA3001395A1 (en) 2017-04-20

Family

ID=54359849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3001395A Pending CA3001395A1 (en) 2015-10-16 2016-10-13 High avidity hpv t-cell receptors

Country Status (7)

Country Link
US (1) US11401316B2 (https=)
EP (2) EP3156067A1 (https=)
JP (1) JP7000315B2 (https=)
CN (1) CN108135998B (https=)
AU (1) AU2016336817C1 (https=)
CA (1) CA3001395A1 (https=)
WO (1) WO2017064198A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
CN109053879B (zh) * 2018-08-22 2020-12-25 深圳市宝安区中心医院 一种治疗宫颈癌的scFv抗体及其应用
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
CN115867295A (zh) * 2020-03-23 2023-03-28 昆士兰医学研究所理事会 用于靶向hpv感染细胞的组合物和方法
WO2021252517A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
CN113801217B (zh) * 2020-06-17 2025-12-23 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的高亲和力t细胞受体
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的tcr
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种针对hpv的高亲和力tcr
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
WO2023014337A1 (en) * 2021-08-04 2023-02-09 GUERRERO PRESTON Rafael Viral and host biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer linked to severe acute respiratory syndrome coronavirus 2 and human papilloma virus
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CN115286698B (zh) * 2022-05-10 2023-09-01 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
EP4583876A1 (en) 2022-09-08 2025-07-16 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
GB202311170D0 (en) * 2023-07-20 2023-09-06 Univ Oxford Innovation Ltd Antigen binding polypeptides
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US20070218080A1 (en) 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
CA2700278A1 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US20150175683A1 (en) 2012-06-26 2015-06-25 Apo-T B.V. Binding molecules targeting pathogens
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing

Also Published As

Publication number Publication date
WO2017064198A1 (en) 2017-04-20
AU2016336817B2 (en) 2021-02-04
AU2016336817C1 (en) 2021-05-13
EP3156067A1 (en) 2017-04-19
AU2016336817A1 (en) 2018-05-31
JP2018535668A (ja) 2018-12-06
EP3362090A1 (en) 2018-08-22
CN108135998B (zh) 2023-05-09
AU2016336817B9 (en) 2021-02-11
US20190062398A1 (en) 2019-02-28
JP7000315B2 (ja) 2022-02-04
CN108135998A (zh) 2018-06-08
US11401316B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
US11401316B2 (en) High avidity HPV T-cell receptors
JP7787119B2 (ja) Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法
TWI840351B (zh) T細胞受體及表現其之工程化細胞
TWI775768B (zh) 新穎t細胞受器及使用其之免疫治療
RU2685479C2 (ru) Химерный антигенный рецептор
KR20200023165A (ko) 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용
JP2019041775A (ja) 細胞
KR20210072784A (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
US20200289564A1 (en) Modified CAR-T
TW201839010A (zh) T細胞受體及其針對prame陽性癌症的免疫治療
CN105377886A (zh) 识别mage-a1的高亲和力结合分子
WO2017219936A1 (zh) 一种高效稳定表达激活型抗体的car-t细胞及其用途
WO2019129177A1 (zh) 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
US20190359677A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
KR102381854B1 (ko) T 세포 수용체 및 이를 사용하는 면역 요법
CN116284389A (zh) 抗afp/hla02 tcr样抗体及其用途
WO2022006147A1 (en) Methods and compositions for the reduction of chimeric antigen receptor tonic signaling
HK40034163A (en) Genetically engineered cell and application thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211012